These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 1358636)

  • 1. Response of monoaminergic and neuropeptide systems to 4-methylaminorex: a new stimulant of abuse.
    Hanson GR; Bunker CF; Johnson M; Bush L; Gibb JW
    Eur J Pharmacol; 1992 Aug; 218(2-3):287-93. PubMed ID: 1358636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neurochemical effects of an acute treatment with 4-methylaminorex: a new stimulant of abuse.
    Bunker CF; Johnson M; Gibb JW; Bush LG; Hanson GR
    Eur J Pharmacol; 1990 May; 180(1):103-11. PubMed ID: 1973111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stimulus properties of some analogues of 4-methylaminorex.
    Russell BR; Beresford RA; Schmierer DM; McNaughton N; Clark CR
    Pharmacol Biochem Behav; 1995; 51(2-3):375-8. PubMed ID: 7667356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stimulus properties of a new designer drug: 4-methylaminorex ("U4Euh").
    Glennon RA; Misenheimer B
    Pharmacol Biochem Behav; 1990 Mar; 35(3):517-21. PubMed ID: 1971111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of 3,4-methylenedioxyamphetamine and 3,4-methylenedioxymethamphetamine isomers on central serotonergic, dopaminergic and nigral neurotensin systems of the rat.
    Johnson M; Letter AA; Merchant K; Hanson GR; Gibb JW
    J Pharmacol Exp Ther; 1988 Mar; 244(3):977-82. PubMed ID: 2472482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Persistence of tolerance to methamphetamine-induced monoamine deficits.
    Danaceau JP; Deering CE; Day JE; Smeal SJ; Johnson-Davis KL; Fleckenstein AE; Wilkins DG
    Eur J Pharmacol; 2007 Mar; 559(1):46-54. PubMed ID: 17239369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute neurochemical and behavioral effects of stereoisomers of 4-methylaminorex in relation to brain drug concentrations.
    Kankaanpää A; Ellermaa S; Meririnne E; Hirsjärvi P; Seppälä T
    J Pharmacol Exp Ther; 2002 Feb; 300(2):450-9. PubMed ID: 11805204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The influence of acute and chronic administration of 1,2-dimethyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline on the function of the nigrostriatal dopaminergic system in rats.
    Lorenc-Koci E; Antkiewicz-Michaluk L; Kamińska A; Lenda T; Zieba B; Wierońska J; Smiałowska M; Schulze G; Rommelspacher H
    Neuroscience; 2008 Oct; 156(4):973-86. PubMed ID: 18809471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation of striatonigral prodynorphin peptides by dopaminergic agents.
    Trujillo KA; Day R; Akil H
    Brain Res; 1990 Jun; 518(1-2):244-56. PubMed ID: 1975215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of a novel and potentially lethal designer drug (±)-cis-para-methyl-4-methylaminorex (4,4'-DMAR, or 'Serotoni').
    Brandt SD; Baumann MH; Partilla JS; Kavanagh PV; Power JD; Talbot B; Twamley B; Mahony O; O'Brien J; Elliott SP; Archer RP; Patrick J; Singh K; Dempster NM; Cosbey SH
    Drug Test Anal; 2014; 6(7-8):684-95. PubMed ID: 24841869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response of extrapyramidal and limbic neuropeptides to fenfluramine administration: comparison with methamphetamine.
    Hanson GR; Singh N; Bush L; Gibb JW
    J Pharmacol Exp Ther; 1991 Dec; 259(3):1197-202. PubMed ID: 1722253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurochemical effects of amphetamine metabolites on central dopaminergic and serotonergic systems.
    Matsuda LA; Hanson GR; Gibb JW
    J Pharmacol Exp Ther; 1989 Dec; 251(3):901-8. PubMed ID: 2600821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rewarding properties of the stereoisomers of 4-methylaminorex: involvement of the dopamine system.
    Meririnne E; Kajos M; Kankaanpää A; Koistinen M; Kiianmaa K; Seppälä T
    Pharmacol Biochem Behav; 2005 Aug; 81(4):715-24. PubMed ID: 15982727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methcathinone: an initial study of its effects on monoaminergic systems.
    Gygi MP; Gibb JW; Hanson GR
    J Pharmacol Exp Ther; 1996 Mar; 276(3):1066-72. PubMed ID: 8786536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of neurotensin-containing neurons in the rat striatum and substantia nigra. Effects of unilateral nigral lesion with 6-hydroxydopamine on neurotensin content and its binding site density.
    Masuo Y; Pélaprat D; Montagne MN; Scherman D; Rostène W
    Brain Res; 1990 Mar; 510(2):203-10. PubMed ID: 1970504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The behavioral effects of the stereoisomers of 4-methylaminorex, a psychostimulant, in the rat.
    Batsche K; Ashby CR; Lee C; Schwartz J; Wang RY
    J Pharmacol Exp Ther; 1994 Jun; 269(3):1029-39. PubMed ID: 7912274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective antagonism of nigral neuropeptide responses to methamphetamine by conantokin G, a naturally occurring conopeptide.
    Bush L; McCabe T; Hanson GR
    Eur J Pharmacol; 2000 Jan; 387(1):55-8. PubMed ID: 10633160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of dopaminergic influence on striatal-nigral neurotensin systems.
    Letter AA; Matsuda LA; Merchant KM; Gibb JW; Hanson GR
    Brain Res; 1987 Sep; 422(1):200-3. PubMed ID: 3119151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Age as a susceptibility factor in the striatal dopaminergic neurotoxicity observed in the mouse following substituted amphetamine exposure.
    Miller DB; O'Callaghan JP; Ali SF
    Ann N Y Acad Sci; 2000 Sep; 914():194-207. PubMed ID: 11085321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of amphetamine-like designer drugs on monoaminergic systems in rat brain.
    Gibb JW; Stone DM; Stahl DC; Hanson GR
    NIDA Res Monogr; 1987; 76():316-21. PubMed ID: 2449619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.